

Gastrointestinal Stromal Tumors (GSTs) Treatment Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/G67E93B473F4EN.html>

Date: March 2022

Pages: 61

Price: US\$ 3,250.00 (Single User License)

ID: G67E93B473F4EN

Abstracts

A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine.

This report contains market size and forecasts of Gastrointestinal Stromal Tumors (GSTs) Treatment in Global, including the following market information:

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Gastrointestinal Stromal Tumors (GSTs) Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Surgery Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gastrointestinal Stromal Tumors (GSTs) Treatment include Pfizer, Bayer, Novartis, Immunium, Roche, AB Science, Arog Pharmaceuticals, Boston Biomedical and Sun Pharmaceutical and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Gastrointestinal Stromal

Tumors (GSTs) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Segment Percentages, by Type, 2021 (%)

Surgery

Targeted Therapy

Radiation Therapy

ChemOthersapy

Others

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Ambulatory Surgical Centers

Others

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market, By Region and

Country, 2017-2022, 2023-2028 (\$ Millions)

Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Segment
Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Gastrointestinal Stromal Tumors (GSTs) Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Gastrointestinal Stromal Tumors (GSTs) Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Bayer

Novartis

Immunicum

Roche

AB Science

Arog Pharmaceuticals

Boston Biomedical

Sun Pharmaceutical

Natco Pharma

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Gastrointestinal Stromal Tumors (GSTs) Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL GASTROINTESTINAL STROMAL TUMORS (GSTS) TREATMENT OVERALL MARKET SIZE

- 2.1 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size: 2021 VS 2028
- 2.2 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Gastrointestinal Stromal Tumors (GSTs) Treatment Players in Global Market
- 3.2 Top Global Gastrointestinal Stromal Tumors (GSTs) Treatment Companies Ranked by Revenue
- 3.3 Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Players

in Global Market

3.6.1 List of Global Tier 1 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size Markets, 2021 & 2028

4.1.2 Surgery

4.1.3 Targeted Therapy

4.1.4 Radiation Therapy

4.1.5 ChemOthersapy

4.1.6 Others

4.2 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue & Forecasts

4.2.1 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2022

4.2.2 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2023-2028

4.2.3 By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Ambulatory Surgical Centers

5.1.5 Others

5.2 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue & Forecasts

5.2.1 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2022

5.2.2 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue, 2023-2028

5.2.3 By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment
Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2021 & 2028

6.2 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue &
Forecasts

6.2.1 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue,
2017-2022

6.2.2 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue,
2023-2028

6.2.3 By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue
Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Gastrointestinal Stromal Tumors (GSTs) Treatment
Revenue, 2017-2028

6.3.2 US Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.3.3 Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2017-2028

6.3.4 Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2017-2028

6.4 Europe

6.4.1 By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment
Revenue, 2017-2028

6.4.2 Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2017-2028

6.4.3 France Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2017-2028

6.4.4 U.K. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.4.5 Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.4.6 Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2017-2028

6.4.7 Nordic Countries Gastrointestinal Stromal Tumors (GSTs) Treatment Market
Size, 2017-2028

6.4.8 Benelux Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size,
2017-2028

6.5 Asia

6.5.1 By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028

6.5.2 China Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.5.3 Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.5.4 South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.5.6 India Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028

6.6.2 Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.6.3 Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028

6.7.2 Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.7.3 Israel Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

6.7.5 UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer

7.1.1 Pfizer Corporate Summary

7.1.2 Pfizer Business Overview

7.1.3 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings

7.1.4 Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global

Market (2017-2022)

7.1.5 Pfizer Key News

7.2 Bayer

7.2.1 Bayer Corporate Summary

7.2.2 Bayer Business Overview

7.2.3 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product

Offerings

7.2.4 Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global

Market (2017-2022)

7.2.5 Bayer Key News

7.3 Novartis

7.3.1 Novartis Corporate Summary

7.3.2 Novartis Business Overview

7.3.3 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product

Offerings

7.3.4 Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global

Market (2017-2022)

7.3.5 Novartis Key News

7.4 Immunicum

7.4.1 Immunicum Corporate Summary

7.4.2 Immunicum Business Overview

7.4.3 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product

Offerings

7.4.4 Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in

Global Market (2017-2022)

7.4.5 Immunicum Key News

7.5 Roche

7.5.1 Roche Corporate Summary

7.5.2 Roche Business Overview

7.5.3 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product

Offerings

7.5.4 Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global

Market (2017-2022)

7.5.5 Roche Key News

7.6 AB Science

7.6.1 AB Science Corporate Summary

7.6.2 AB Science Business Overview

7.6.3 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product

Offerings

7.6.4 AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)

7.6.5 AB Science Key News

7.7 Arog Pharmaceuticals

7.7.1 Arog Pharmaceuticals Corporate Summary

7.7.2 Arog Pharmaceuticals Business Overview

7.7.3 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings

7.7.4 Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)

7.7.5 Arog Pharmaceuticals Key News

7.8 Boston Biomedical

7.8.1 Boston Biomedical Corporate Summary

7.8.2 Boston Biomedical Business Overview

7.8.3 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings

7.8.4 Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)

7.8.5 Boston Biomedical Key News

7.9 Sun Pharmaceutical

7.9.1 Sun Pharmaceutical Corporate Summary

7.9.2 Sun Pharmaceutical Business Overview

7.9.3 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings

7.9.4 Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)

7.9.5 Sun Pharmaceutical Key News

7.10 Natco Pharma

7.10.1 Natco Pharma Corporate Summary

7.10.2 Natco Pharma Business Overview

7.10.3 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Major Product Offerings

7.10.4 Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global Market (2017-2022)

7.10.5 Natco Pharma Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Opportunities & Trends in Global Market

Table 2. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Drivers in Global Market

Table 3. Gastrointestinal Stromal Tumors (GSTs) Treatment Market Restraints in Global Market

Table 4. Key Players of Gastrointestinal Stromal Tumors (GSTs) Treatment in Global Market

Table 5. Top Gastrointestinal Stromal Tumors (GSTs) Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Gastrointestinal Stromal Tumors (GSTs) Treatment Product Type

Table 9. List of Global Tier 1 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Gastrointestinal Stromal Tumors (GSTs) Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Gastrointestinal Stromal Tumors (GSTs)

Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Gastrointestinal Stromal Tumors (GSTs)

Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment

Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Gastrointestinal Stromal Tumors (GSTs)

Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Gastrointestinal Stromal Tumors (GSTs)

Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs)

Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs)

Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer Corporate Summary

Table 31. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 32. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Bayer Corporate Summary

Table 34. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 35. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Novartis Corporate Summary

Table 37. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 38. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Immunicum Corporate Summary

Table 40. Immunicum Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 41. Immunicon Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Roche Corporate Summary

Table 43. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 44. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. AB Science Corporate Summary

Table 46. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 47. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Arog Pharmaceuticals Corporate Summary

Table 49. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 50. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Boston Biomedical Corporate Summary

Table 52. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 53. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Sun Pharmaceutical Corporate Summary

Table 55. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 56. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Natco Pharma Corporate Summary

Table 58. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Product Offerings

Table 59. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Gastrointestinal Stromal Tumors (GSTs) Treatment Segment by Type in 2021
- Figure 2. Gastrointestinal Stromal Tumors (GSTs) Treatment Segment by Application in 2021
- Figure 3. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue in 2021
- Figure 8. By Type - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
- Figure 12. US Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$,

Mn), 2017-2028

Figure 20. Russia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028

Figure 24. China Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Bayer Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Novartis Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Immunomicum Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Roche Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. AB Science Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Arog Pharmaceuticals Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Boston Biomedical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Sun Pharmaceutical Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Natco Pharma Gastrointestinal Stromal Tumors (GSTs) Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Gastrointestinal Stromal Tumors (GSTs) Treatment Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/G67E93B473F4EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G67E93B473F4EN.html>